Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 38 clinical trials
featured
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK

crizotinib
lung cancer
lung carcinoma
  • 98 views
  • 23 Nov, 2020
  • 1 location
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are

metastasis
crizotinib
  • 976 views
  • 24 Dec, 2020
  • 221 locations
Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors

there is no standardized approach to the treatment of IMT in children worldwide. This study can show the benefits of the usage of crizotinib as targeted therapy in children with ALK/ROS1

  • 0 views
  • 23 Jan, 2021
  • 1 location
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Crizotinib is a first-generation ALK tyrosine kinase inhibitor (ITK-ALK). It is the standard first-line treatment for patients with advanced NSCLC with ALK gene rearrangement. Alectinib

  • 0 views
  • 25 Jan, 2021
  • 30 locations
A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

A Phase 2, multi center, open label, dual cohort study to evaluate the efficacy and safety of lorlatinib (PF 06463922) monotherapy in ALK inhibitor treated locally advanced or metastatic ALK positive non small cell lung cancer patients in China

follicle stimulating hormone
secondary malignant neoplasm of liver
metastasis
serum bilirubin level
lipase
  • 15 views
  • 25 Jan, 2021
  • 24 locations
An Efficacy Study Comparing Brigatinib Versus Alectinib in Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small-Cell Lung Cancer (NSCLC) Participants Who Have Progressed on Crizotinib

The purpose of this study is to compare the efficacy of brigatinib versus alectinib in participants with ALK+ locally advanced or metastatic NSCLC who have progressed on crizotinib as evidenced

  • 19 views
  • 25 Jan, 2021
  • 117 locations
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

-squamous non-small cell lung cancer. Lorlatinib, ceritinib, alectinib, brigatinib, ensartinib, and crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

tyrosine
carboplatin
lorlatinib
gilbert's syndrome
brigatinib
  • 143 views
  • 15 Jan, 2021
  • 387 locations
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

cancer
carboplatin
metastasis
paclitaxel
gemcitabine
  • 1103 views
  • 17 Jan, 2021
  • 1105 locations
Study of Crizotinib for ROS1 and MET Activated Lung Cancer

This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes

cancer
squamous non-small cell lung cancer
measurable disease
ROS1
crizotinib
  • 0 views
  • 25 Jan, 2021
  • 1 location
Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

This study is to allow access to crizotinib who were treated in previous Pfizer-sponsored studies in China.

  • 0 views
  • 25 Jan, 2021
  • 11 locations